- Home
- NFJ vs ATAI Comparison
NFJ vs ATAI Comparison
Compare NFJ & ATAI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | NFJ | ATAI |
|---|---|---|
| Founded | 2005 | 2018 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Finance: Consumer Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.2B | 1.3B |
| IPO Year | N/A | 2021 |
Fundamental Metrics
Financial Performance| Metric | NFJ | ATAI |
|---|---|---|
| Price | $12.68 | $3.79 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 8 |
| Target Price | N/A | ★ $15.13 |
| AVG Volume (30 Days) | 218.6K | ★ 3.9M |
| Earning Date | 01-01-0001 | 05-06-2026 |
| Dividend Yield | ★ 9.01% | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $308,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $10.61 | $1.15 |
| 52 Week High | $13.92 | $6.73 |
Technical Indicators
Market Signals| Indicator | NFJ | ATAI |
|---|---|---|
| Relative Strength Index (RSI) | 48.15 | 53.19 |
| Support Level | $12.73 | $3.60 |
| Resistance Level | $12.80 | $4.30 |
| Average True Range (ATR) | 0.20 | 0.20 |
| MACD | 0.06 | 0.04 |
| Stochastic Oscillator | 75.25 | 70.21 |
Price Performance
Historical ComparisonAbout NFJ Virtus Dividend Interest & Premium Strategy Fund of Beneficial Interest
Virtus Dividend, Interest & Premium Strategy Fund is a Massachusetts-based business trust. The primary investment objective of the company is to seek current income and gains, with a secondary objective of long-term capital appreciation. The fund pursues its investment objectives by investing in a diversified portfolio of dividend-paying common stocks and income-producing convertible securities.
About ATAI ATAI Life Sciences N.V.
AtaiBeckley Inc is a clinical-stage biopharmaceutical company on a mission to transform patient outcomes by developing effective, rapid-acting, and convenient mental health treatments. AtaiBeckley's pipeline of novel therapies includes BPL-003 (mebufotenin benzoate nasal spray) for treatment-resistant depression (TRD), VLS-01 (DMT buccal film) for TRD and EMP-01 ((R)-MDMA HCI) for social anxiety disorder, which are in Phase 2 clinical development.